Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1859699

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1859699

Global Artificial Intelligence (AI) in Clinical Trials Market

PUBLISHED:
PAGES: 153 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4650
PDF & Excel (2-5 Users)
USD 5580
PDF & Excel (Site License)
USD 6696
PDF & Excel (Enterprise License)
USD 8035

Add to Cart

The global market for Artificial Intelligence (AI) in Clinical Trials was valued at $2 billion in 2024 and is estimated to increase from $2.4 billion in 2025 to reach $6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.

The North American market for AI in Clinical Trials was valued at $771.2 million in 2024 and is estimated to increase from $936.7 million in 2025 to reach $2.7 billion by 2030, at a CAGR of 23.7% from 2025 through 2030.

The Asia-Pacific market for AI in Clinical Trials was valued at $372.8 million in 2024 and is estimated to increase from $467.9 million in 2025 to reach $1.6 billion by 2030, at a CAGR of 28.4% from 2025 through 2030.

Report Scope

The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.

The report's regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.

It includes global revenue ($ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

Report Includes

  • 56 data tables and 52 additional tables
  • In-depth analysis of the global market for artificial intelligence (AI) in pharmaceutical clinical trials
  • Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
  • Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by offerings, deployment type, trial phase, therapeutic area, end user and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
  • Impact analysis of U.S. tariff laws on AI in the clinical trials market
  • Insights derived from Porter's Five Forces model, as well as a global supply chain analysis
  • A look at the regulatory landscape featuring key international and regional regulations and standards for AI adoption
  • Evaluation of recent patent activity and key granted and published patents
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
  • Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Company profiles of major players within the industry, including IQVIA, Medidata, Saama, Merative, and Nvidia Corp.
Product Code: PHM285A

Table of Contents

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Overview
  • Future Outlook
  • Macroeconomic Factors
  • Global GDP Growth
  • Demographic Factors
  • Impact of U.S. Tariffs
  • Porter's Five Forces Analysis
  • Impact of AI Adoption on Clinical Trials Market
  • Overview
  • Use Cases/Case Studies
  • Use Case 1: Oncology Patient Recruitment
  • Use Case 2: Accelerating Data Processing in Infectious Disease Vaccine Trials
  • Use Case 3: Enhancing Patient Retention in Alzheimer's Disease Trials
  • AI Adoption: Clinical Trials
  • Adoption Trends at Regional/Country Levels
  • AI Disruption Trends
  • Impact of AI on Industry Verticals
  • Impact of AI on the Value Chain
  • Market Spending and Investment
  • Market Spending and Forecasting Analysis
  • Venture Capital Investment in AI Focused on Clinical Trials

Chapter 3 Market Dynamics

  • Market Drivers
  • Need for a Faster Drug Development Process
  • AI-driven Clinical Trials
  • Advanced Data Handling for Complex Clinical Input
  • Market Restraints
  • Data Privacy and Security Concerns
  • Regulatory Uncertainties
  • High Costs and Technical Complexity
  • Market Opportunities
  • Accelerated Trials Through Adaptive AI Design
  • AI-Augmented Remote Patient Monitoring

Chapter 4 Regulatory Landscape

  • Regulatory Framework

Chapter 5 Emerging Technologies

  • Overview
  • Emerging Technologies
  • Machine Learning for Predictive Analytics and Stratification
  • Digital Twin Technology
  • NLP for Extracting Insights from Unstructured Data
  • AI-Powered Trial Design and Optimization
  • Blockchain for Secure Clinical Data Management
  • Decentralized and Virtual Trial Platforms
  • Remote Monitoring Via Wearable Technologies
  • Generative AI for Protocol Authoring
  • Real-World Evidence Integration in Clinical Trials
  • Cloud-based AI Platforms for Scalable Deployment
  • Clinical Trial Analysis
  • Takeaways

Chapter 6 Market Segmentation Analysis

  • Segmentation Breakdown
  • Global Market for AI in Clinical Trials, by Component
  • Takeaways
  • Software
  • Services
  • Global AI in Clinical Trials Market, by Phase
  • Takeaways
  • Phase III
  • Phase II Trials
  • Phase I
  • Phase IV Clinical Trials
  • Global Market for AI in Clinical Trials, by Deployment Mode
  • Takeaways
  • Cloud
  • On-premise
  • Hybrid Deployments
  • Global Market for AI in Clinical Trials, by Therapeutic Area
  • Takeaways
  • Oncology
  • Infectious Disease Clinical Trials
  • Neurological Diseases
  • Other Conditions
  • Global Market for AI in Clinical Trials, by End User
  • Takeaways
  • Pharmaceutical and Biotech Companies
  • Contract Research Organizations
  • Research and Academic Institutes
  • Other End Users
  • Geographic Breakdown
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America

Chapter 7 Competitive Intelligence

  • Overview

Chapter 8 Sustainability in AI in Clinical Trials: ESG Perspective

  • Sustainability Trends and AI Initiatives
  • Concluding Remarks

Chapter 9 Appendix

  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • AICURE
  • CONCERTAI
  • DNANEXUS INC.
  • INSILICO MEDICINE
  • INTELLIGENCIA AI
  • IQVIA
  • MEDIDATA
  • MERATIVE
  • NVIDIA CORP.
  • PHESI
  • SAAMA
  • TEMPUS
  • TRINETX LLC
  • TRIOMICS
  • UNLEARN.AI INC.
  • Emerging Start-ups/ Market Disruptors
Product Code: PHM285A

List of Tables

  • Summary Table : Global Market for AI in Clinical Trials, by Region, Through 2030
  • Table 1 : Real GDP Growth, by Country, 2022-2025
  • Table 2 : Venture Capital Funding for U.S. Companies on AI for Clinical Trials
  • Table 3 : VC Investment in AI Focused on Clinical Trials
  • Table 4 : Regulations Pertaining to AI in Clinical Trials
  • Table 5 : Clinical Trials Studies
  • Table 6 : Global Market for AI in Clinical Trials, by Component, Through 2030
  • Table 7 : Global Market for AI Software in Clinical Trials, by Region, Through 2030
  • Table 8 : Global Market for Services Related to AI in Clinical Trials, by Region, Through 2030
  • Table 9 : Global Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 10 : Global Market for AI in Phase III Clinical Trials, by Region, Through 2030
  • Table 11 : Global Market for AI in Phase II Clinical Trials, by Region, Through 2030
  • Table 12 : Global Market for AI in Phase I Clinical Trials, by Region, Through 2030
  • Table 13 : Global Market for AI in Phase IV Clinical Trials, by Region, Through 2030
  • Table 14 : Global Market for AI in Clinical Trials, by Deployment Mode, Through 2030
  • Table 15 : Global Market for Cloud Deployments of AI in Clinical Trials, by Region, Through 2030
  • Table 16 : Global Market for On-Premise Deployments of AI in Clinical Trials, by Region, Through 2030
  • Table 17 : Global Market for Hybrid Deployments of AI in Clinical Trials, by Region, Through 2030
  • Table 18 : Global Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
  • Table 19 : Global Market for AI in Oncology Clinical Trials, by Region, Through 2030
  • Table 20 : Global Market for AI in Infectious Disease Clinical Trials, by Region, Through 2030
  • Table 21 : Global Market for AI in Neurological Disease Clinical Trials, by Region, Through 2030
  • Table 22 : Global Market for AI in Clinical Trials for Other Conditions, by Region, Through 2030
  • Table 23 : Global Market for AI in Clinical Trials, by End User, Through 2030
  • Table 24 : Global Market for AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, Through 2030
  • Table 25 : Global Market for AI Used in Clinical Trials by CROs, by Region, Through 2030
  • Table 26 : Global Market for AI Used in Clinical Trials by Research and Academic Institutes, by Region, Through 2030
  • Table 27 : Global Market for AI Used by Other End Users in Clinical Trials, by Region, Through 2030
  • Table 28 : Global Market for AI in Clinical Trials, by Region, Through 2030
  • Table 29 : North American Market for AI in Clinical Trials, by Component, Through 2030
  • Table 30 : North American Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 31 : North American Market for AI in Clinical Trials, by Deployment Mode, Through 2030
  • Table 32 : North American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
  • Table 33 : North American Market for AI in Clinical Trials, by End User, Through 2030
  • Table 34 : North American Market for AI in Clinical Trials, by Country, Through 2030
  • Table 35 : European Market for AI in Clinical Trials, by Component, Through 2030
  • Table 36 : European Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 37 : European Market for AI in Clinical Trials, by Deployment Mode, Through 2030
  • Table 38 : European Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
  • Table 39 : European Market for AI in Clinical Trials, by End User, Through 2030
  • Table 40 : European Market for AI in Clinical Trials, by Country, Through 2030
  • Table 41 : Asia-Pacific Market for AI in Clinical Trials, by Component, Through 2030
  • Table 42 : Asia-Pacific Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 43 : Asia-Pacific Market for AI in Clinical Trials, by Deployment Mode, Through 2030
  • Table 44 : Asia-Pacific Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
  • Table 45 : Asia-Pacific Market for AI in Clinical Trials, by End User, Through 2030
  • Table 46 : Asia-Pacific Market for AI in Clinical Trials, by Country, Through 2030
  • Table 47 : MEA Market for AI in Clinical Trials, by Component, Through 2030
  • Table 48 : MEA Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 49 : MEA Market for AI in Clinical Trials, by Deployment Mode, Through 2030
  • Table 50 : MEA Market for AI in Clinical Trials, by Therapeutic Area, Through 2030
  • Table 51 : MEA Market for AI in Clinical Trials, by End User, Through 2030
  • Table 52 : MEA Market for AI in Clinical Trials, by Sub-Region, Through 2030
  • Table 53 : South American Market for AI in Clinical Trials, by Component, Through 2030
  • Table 54 : South American Market for AI in Clinical Trials, by Phase, Through 2030
  • Table 55 : South American Market for AI in Clinical Trials, by Deployment Mode,Through 2030
  • Table 56 : South American Market for AI in Clinical Trials, by Therapeutic Area,Through 2030
  • Table 57 : South American Market for AI in Clinical Trials, by End User, Through 2030
  • Table 58 : South American Market for AI in Clinical Trials, by Country, Through 2030
  • Table 59 : Global Ranking of Players in AI in Clinical Trials Industry, 2024
  • Table 60 : Strategic Initiatives, 2024 and 2025
  • Table 61 : Information Sources Used in Preparing this Report
  • Table 62 : Abbreviations Used in this Report
  • Table 63 : AiCure: Company Snapshot
  • Table 64 : AiCure: Product Portfolio
  • Table 65 : AiCure: News/Key Developments, 2022
  • Table 66 : ConcertAI: Company Snapshot
  • Table 67 : ConcertAI: Product Portfolio
  • Table 68 : ConcertAI: News/Key Developments, 2023 and 2024
  • Table 69 : DNAnexus Inc.: Company Snapshot
  • Table 70 : DNAnexus Inc: Product Portfolio
  • Table 71 : DNAnexus Inc: News/Key Developments, 2024 and 2025
  • Table 72 : Insilico Medicine: Company Snapshot
  • Table 73 : Insilico Medicine: Product Portfolio
  • Table 74 : Insilico Medicine: News/Key Developments, 2023-2025
  • Table 75 : Intelligencia AI: Company Snapshot
  • Table 76 : Intelligencia AI: Product Portfolio
  • Table 77 : IQVIA: Company Snapshot
  • Table 78 : IQVIA: Financial Performance, FY 2023 and 2024
  • Table 79 : IQVIA: Product Portfolio
  • Table 80 : IQVIA: News/Key Developments, 2025
  • Table 81 : Medidata: Company Snapshot
  • Table 82 : Medidata: Product Portfolio
  • Table 83 : Medidata: News/Key Developments, 2023-2025
  • Table 84 : Merative: Company Snapshot
  • Table 85 : Merative: Product Portfolio
  • Table 86 : Nvidia Corp.: Company Snapshot
  • Table 87 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
  • Table 88 : Nvidia Corp.: Product Portfolio
  • Table 89 : Nvidia Corp.: News/Key Developments, 2023-2025
  • Table 90 : Phesi: Company Snapshot
  • Table 91 : Phesi: Product Portfolio
  • Table 92 : Phesi: News/Key Developments, 2022-2025
  • Table 93 : Saama: Company Snapshot
  • Table 94 : Saama: Product Portfolio
  • Table 95 : Saama: News/Key Developments, 2023 and 2024
  • Table 96 : Tempus: Company Snapshot
  • Table 97 : Tempus: Product Portfolio
  • Table 98 : Tempus: News/Key Developments, 2022-2025
  • Table 99 : TriNetX LLC.: Company Snapshot
  • Table 100 : TriNetX LLC: Product Portfolio
  • Table 101 : TriNetX LLC: News/Key Developments, 2025
  • Table 102 : Triomics: Company Snapshot
  • Table 103 : Triomics: Product Portfolio
  • Table 104 : Unlearn.ai Inc.: Company Snapshot
  • Table 105 : Unlearn.ai Inc.: Product Portfolio
  • Table 106 : Unlearn.ai Inc.: News/Key Developments, 2022 and 2025
  • Table 107 : Emerging Startups

List of Figures

  • Summary Figure : Global Market Shares of AI in Clinical Trials, by Region, 2024
  • Figure 1 : Porter's Five Forces Analysis
  • Figure 2 : Market Dynamics of Artificial Intelligence in Clinical Trials Market
  • Figure 3 : Global Market Shares of AI in Clinical Trials, by Component, 2024
  • Figure 4 : Global Market Shares of AI Software in Clinical Trials, by Region, 2024
  • Figure 5 : Global Market Shares of Services Related to AI in Clinical Trials, by Region, 2024
  • Figure 6 : Global Market Shares of AI in Clinical Trials, by Phase, 2024
  • Figure 7 : Global Market Shares of AI in Phase III Clinical Trials, by Region, 2024
  • Figure 8 : Global Market Shares of AI in Phase II Clinical Trials, by Region, 2024
  • Figure 9 : Global Market Shares of AI in Phase I Clinical Trials, by Region, 2024
  • Figure 10 : Global Market Shares of AI in Phase IV Clinical Trials, by Region, 2024
  • Figure 11 : Global Market Shares of AI in Clinical Trials, by Deployment Mode, 2024
  • Figure 12 : Global Market Shares of Cloud Deployments of AI in Clinical Trials, by Region, 2024
  • Figure 13 : Global Market Shares of On-Premise Deployments of AI in Clinical Trials, by Region, 2024
  • Figure 14 : Global Market Shares of Hybrid Deployments of AI in Clinical Trials, by Region, 2024
  • Figure 15 : Global Market Shares of AI in Clinical Trials, by Therapeutic Area, 2024
  • Figure 16 : Global Market Shares of AI in Oncology Clinical Trials, by Region, 2024
  • Figure 17 : Global Market Shares of AI in Infectious Disease Clinical Trials, by Region, 2024
  • Figure 18 : Global Market Shares of AI in Neurological Disease Clinical Trials, by Region, 2024
  • Figure 19 : Global Market Shares of AI in Clinical Trials for Other Conditions, by Region, 2024
  • Figure 20 : Global Market Shares of AI in Clinical Trials, by End User, 2024
  • Figure 21 : Global Market Shares of AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, 2024
  • Figure 22 : Global Market Shares of AI Used in Clinical Trials by CROs, by Region, 2024
  • Figure 23 : Global Market Shares of AI Used in Clinical Trials by Research and Academic Institutes, by Region, 2024
  • Figure 24 : Global Market Shares of AI Used by Other End Users in Clinical Trials, by Region, 2024
  • Figure 25 : Global Market Shares of AI in Clinical Trials, by Region, 2024
  • Figure 26 : North American Market Shares of AI in Clinical Trials, by Country, 2024
  • Figure 27 : European Market Shares of AI in Clinical Trials, by Country, 2024
  • Figure 28 : Asia-Pacific Market Shares of AI in Clinical Trials, by Country, 2024
  • Figure 29 : MEA Market Shares of AI in Clinical Trials, by Sub-Region, 2024
  • Figure 30 : South American Market Shares of AI in Clinical Trials, by Country, 2024
  • Figure 31 : IQVIA: Revenue Shares, by Business Unit, FY 2024
  • Figure 32 : IQVIA: Revenue Shares, by Country/Region, FY 2024
  • Figure 33 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
  • Figure 34 : Nvidia Corp.: Revenue Share, by Country/Region, FY 2024
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!